Pyrimidine Triones as Potential Activators of p53 Mutants

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The p53 protein is a critical tumor suppressor frequently inactivated by mutations in human cancers.
• Missense mutations in p53 often lead to loss of tumor-suppressive functions, driving cancer initiation and progression.
• Developing drugs to restore wild-type p53 conformation is a key strategy in personalized cancer therapy.

Purpose of the Study:

• To identify and evaluate novel small-molecule compounds that can correct various p53 mutations.
• To investigate the therapeutic potential of the UCI-1001 compound series in p53-mutant cancer models.

Main Methods:

• Screening of the UCI-1001 compound series for p53 mutation correction activity.
• Assessing the effects of UCI-1001 on cancer cell proliferation, p53 DNA binding, target gene activation, and apoptosis induction.
• Utilizing cellular thermal shift assays, immunofluorescence staining, and differential scanning fluorometry to determine UCI-1001's mechanism of action on p53 conformation.

Main Results:

• UCI-1001 treatment inhibited growth in p53-mutant cancer cell lines.
• The compound successfully reinstated wild-type p53 activities, including DNA binding and induction of cell death.
• Evidence suggests UCI-1001 interacts with mutant p53, altering its conformation towards a wild-type-like state.

Conclusions:

• The UCI-1001 compound series, particularly pyrimidine trione derivatives, shows potential as p53-restoring drugs.
• These findings support the development of UCI-1001 as a targeted therapy for cancers with specific p53 mutations.
• Reactivating mutant p53 holds promise for effective personalized cancer treatment strategies.